In This Section      
Home > Heart & Vascular Institute > Cardiology > Ciccarone Center > Collections
 

Ciccarone Articles

Ciccarone Center Research

Topic

Cholesterol / Lipids / Statins

Landmark Articles

Headed in the right direction but at risk for miscalculation: a critical appraisal of the 2013 ACC/AHA risk assessment guideline.
By: Amin NP, Martin SS, Blaha MJ, Nasir K, Blumenthal RS, Michos ED.
The newly released 2013 ACC/AHA Guideline for Assessing Cardiovascular Risk was a major advance over prior guidelines, but the new risk equations do not appear to lead to significantly better discrimination than older models. Since the same risk factors are incorporated, using the new risk estimators may lead to inaccurate assessment of atherosclerotic cardiovascular risk in certain groups of patients. There also is likely an overestimation of risk when applied to modern populations. Future guidelines could provide clearer direction on which individuals would benefit from additional testing for more personalized preventive therapies.
Read on Pubmed
HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: The Lipoprotein Investigators Collaborative.
By: Martin SS, Khokhar AA, May HT, Kulkarni KR, Blaha MJ, Joshi PH, Toth PP, Muhlestein JB, Anderson JL, Knight S, Li Y, Spertus JA, Jones SR; on behalf of the Lipoprotein Investigators Collaborative (LIC).
In secondary prevention, increased risk for long-term hard clinical events is associated with low HDL3-C, but not HDL2-C or HDL-C, highlighting the potential value of subclassifying HDL-C.
Read on Pubmed
2013 American cholesterol treatment guideline: what was done well and what could be done better.
By: Martin SS, Abd TT, Jones SR, Michos ED, Blumenthal RS, Blaha MJ.
This article critically appraises the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol. The guideline succeeds in prioritizing statin therapy, expanding focus to atherosclerotic cardiovascular disease including stroke, and in emphasizing absolute cardiovascular risk to determine statin eligibility.
Read on Pubmed
Letter by Jones et al regarding article, “Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation.”
By: Jones SR, Martin SS, Brinton EA.
Read on Pubmed
The fascinating story of PCSK9 Inhibition: Insights and perspective from ACC.14.
By: Joshi PH, Martin SS, Blumenthal RS.

The development of PCSK9 inhibitors is coming along at a unique point in the realm of preventive cardiology from multiple perspectives.

Genetically low triglycerides and mortality: further support for “the earlier the better”?
By: Martin SS, Blaha MJ.
Read on Pubmed
2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults.
By: Abd TT, Misra S, Ojeifo O, Martin SS, Blumenthal RS, Foody J, Wong ND.
Read on Pubmed
Narrowing sex differences in lipoprotein cholesterol subclasses following mid-life: the very large database of lipids (VLDL-10B).
By: Swiger KJ, Martin SS, Blaha MJ, Toth PP, Nasir K, Michos ED, Gerstenblith G, Blumenthal RS, Jones SR.
The narrowing sex differential in CVD risk after midlife is mirrored by a higher total atherogenic lipoprotein cholesterol burden in women and a closer approximation of the less favorable density phenotype characteristic of men.
Read on Pubmed
2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk.
By: Abd TT, Misra S, Ojeifo O, Martin SS, Blumenthal RS, Foody J, Wong ND.
The 2013 lifestyle guidelines provide guidance in three narrowly focused areas: 1) the effect of dietary patterns and macronutrient composition on CVD risk factors; 2) the effect of sodium and potassium on CVD risk factors; and 3) the effect of physical activity on blood pressure and lipids.
Read on Pubmed
Focused update on the 2013-2014 cardiovascular disease prevention guidelines.
By: Abd TT, Misra S, Ojeifo O, Martin SS, Blumenthal RS, Foody J, Wong ND.